Levetiracetam
Levetiracetam
CLINICAL USE
Anti-epileptic agent
DOSE IN NORMAL RENAL FUNCTION
250 mg – 1.5 g twice daily
PHARMACOKINETICS
Molecular weight                           :170.2 %Protein binding                           : <10           : %Excreted unchanged in urine     : 66 (95% drug + metabolite) Volume of distribution (L/kg)       :0.5–0.7half-life – normal/ESRD (hrs)      :6–8/25 DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
50–79 500–1000 mg twice daily130–49 250–750 mg twice daily1<30 250–500 mg twice daily1 DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Likely dialysability. 750 mg loading dose then 500–1000 mg daily HD                     :Dialysed. 750 mg loading dose then 500–1000 mg once dailyHDF/high flux   :Dialysed. 750 mg loading dose then 500–1000 mg once dailyCAV/VVHD      :Likely dialysability. Dose as in GFR=30–49 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAntidepressants: antagonism of anticonvulsant effect (convulsive threshold lowered)Antimalarials: mefloquine antagonises anticonvulsant effect; chloroquine and hydroxychloroquine occasionally reduce seizure threshold ADMINISTRATION
Reconstition
– Route
Oral, IV Rate of Administration
15 minutes Comments
Dilute in 100 mL sodium chloride or glucose 5% OTHER INFORMATION
51% of the dose is removed with 4 hours of haemodialysisThe inactive metabolite (ucb L057) accumulates in renal failure
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home